Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genotypic susceptibility score (GSS) and CD4+ T cell recovery in HIV-1 patients with suppressed viral load.

The Journal of antimicrobial chemotherapy - 1 Feb 2017

Gonzalez-Serna Alejandro, Glas Arie C, Brumme C J, Poon Art F Y, Nohpal De La Rosa Adriana, Mudrikova Tania, Dias Lima Viviane, Wensing Annemarie M J, Harrigan Richard

Abstract excerpt

OBJECTIVES: HIV drug resistance, measured by the genotypic susceptibility score (GSS), has a deleterious effect on the virological outcome of HIV-1-infected patients. However, it is not known if GSS retains any predictive value for CD4 recovery in patients with suppressed viral load. METHODS: Four hundred and six patients on virological failure (>500 copies/mL) with GSS : <6 months prior to switch therapy who...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Antiretroviral Therapy, Highly Active

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD4 Lymphocyte Count

Share to CD4-Positive T-Lymphocytes

Share to Drug Resistance, Viral

Share to HIV Infections

Share to Viral Load

Share to Viremia

Source

Identifiers

PMID: 27999069
DOI: 10.1093/jac/dkw455

Genes

GSS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotypic susceptibility score (GSS) and CD4+ T cell recovery in HIV-1 patients with suppressed viral load.PMID 27999069Read ↗

Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment.Semantic proximity Read ↗

High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort.Semantic proximity Read ↗

The impact of HIV drug resistance testing on changes to treatment.Semantic proximity Read ↗

Efficacy of raltegravir switching strategies in HIV-infected patients with suppressed viraemia according to the genotypic sensitivity score.Semantic proximity Read ↗

Virologic Outcomes of Switching to Dolutegravir Functional Monotherapy, or Functional Dual Therapy With Dolutegravir Plus A Non-cytosine Nucleoside Analog: A Retrospective Study of Treatment-Experienced, HIV-1 Infected PatientsSemantic proximity Read ↗

Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES studySemantic proximity Read ↗

Maraviroc, as a Switch Option, in HIV-1–infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH StudySemantic proximity Read ↗

Does GSS still maintain relevance on HAART outcome after the introduction of newest active antiretroviral drugs? 48 weeks results.Semantic proximity Read ↗

Management of antiretroviral therapy for HIV infection: modelling when to change therapy.Semantic proximity Read ↗

Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.Semantic proximity Read ↗

Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333.Semantic proximity Read ↗

Candida albicans switch phenotypes display differential levels of fitness.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.